Silvia Deaglio, MD, PhD
Is Professor of Genetics at the University of Turin, Italy and Director of the Biobank at the Department of Medical Sciences.
Dr Deaglio is internationally recognized for significant contributions to the biology and immunology of chronic lymphocytic leukemia (CLL), especially in areas of microenvironment interactions, immune checkpoints, and disease resistance mechanisms.
Adrian Wiestner, MD, PhD
Is the Senior Investigator and Principal Investigator at the National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, USA.
Dr. Adrian Wiestner leads the Laboratory of Lymphoid Malignancies (Hematology Branch), focusing on improving treatment for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
He is pursuing three major goals: First, identify pathogenic mechanisms to assist the development of targeted therapy. Second, evaluate novel agents and treatment concepts in clinical trials. Third, investigate resistance mechanisms through pharmacodynamic and genetic studies in patients enrolled on clinical trials.